(Q35050740)

6 August 2017

title

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma (English)

1 reference

Vassiliki Papadimitrakopoulou

6 August 2017

main subject

dasatinib monohydrate

1 reference

1 reference

11

object named as

Vassiliki A Papadimitrakopoulou

1 reference

6 August 2017

5

Lawrence E Ginsberg

1 reference

6 August 2017

Heather D Brooks

1

1 reference

6 August 2017

Bonnie S Glisson

2

1 reference

6 August 2017

B Nebiyou Bekele

3

1 reference

6 August 2017

Faye M Johnson

4

1 reference

6 August 2017

Adel El-Naggar

6

1 reference

6 August 2017

Kirk S Culotta

7

1 reference

6 August 2017

Naoko Takebe

8

1 reference

6 August 2017

John Wright

9

1 reference

6 August 2017

Hai T Tran

10

1 reference

6 August 2017

language of work or name

English

0 references

publication date

29 November 2010

1 reference

6 August 2017

1 reference

6 August 2017

volume

117

1 reference

6 August 2017

issue

10

1 reference

6 August 2017

page(s)

2112-2119

1 reference

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Role of Src expression and activation in human cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117018

Metabolism and disposition of dasatinib after oral administration to humans

8 July 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25769

Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25769

Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using luminex technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25769

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25769

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25769

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25769

Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21523723

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21523723

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21523723

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.25769

1 reference

6 August 2017

1 reference

6 August 2017

1 reference